Your Messages Inbox
See All Messages (Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Your Article Summary
Long-term efalizumab therapy for patients with moderate-to-severe, chronic plaque psoriasis
International Journal of Dermatology, 11/25/09
Foley P et al. – Efalizumab, 1.0 mg/kg/week, is effective and well tolerated in a 'real world' clinical setting, providing enduring reduction of psoriasis symptoms for up to 21 months.
Related Articles
Pediatric psoriasis: an update
Therapeutics and Clinical Risk Management, 10/22/09
Relevance Score: 95%
FDA Approves New Drug to Treat Psoriasis
Internet Source, 11/02/09
Relevance Score: 91%
Study shows major burden of psoriasis
Internet Source, 10/29/09
Relevance Score: 91%
Prevalence of myocardial infarction in patients with psoriasis in central China
Journal of the European Academy of Dermatology and Venereology, 10/27/09
Relevance Score: 91%
Why nail psoriasis remains difficult to treat
Dermatology in Practice, 10/12/09
Relevance Score: 91%
Today in Dermatology...keeping you current
Receive free subspecialty "5-minute updates" via email
Nutrition Management of Pressure Ulcers
Nutrition in Clinical Practice, 02/09/10
Recognizing and Treating Toilet-Seat Contact Dermatitis in Children
Pediatrics, 02/09/10
Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre
British Journal of Dermatology, 02/09/10
Article Search
Sponsor
Sponsor